Creation of an anthropomorphic CT head phantom for verification of image segmentation
Abstract
Many methods are available to segment structural magnetic resonance (MR) images of the brain into different tissue types. These have generally been developed for research purposes but there is some clinical use in the diagnosis of neurodegenerative diseases such as dementia. The potential exists for computed tomography (CT) segmentation to be used in place of MRI segmentation, but this will require a method to verify the accuracy of CT processing, particularly if algorithms developed for MR are used, as MR has notably greater tissue contrast.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 31, 2020
- Source ID
- 10.1002/mp.14127
Entities
People
- Gareth C. Thorne
- Ian S. Negus
- Peter Young
- Robin B. Holmes
- Sophie J. Wiltshire
- The Alzheimer’s Disease Neuroimaging Initiative*
Organizations
- AbbVie
- BioClinica
- Biogen
- Bristol-Myers Squibb
- Chiron Corporation
- Eli Lilly and Company
- GE HealthCare
- Hoffmann-La Roche
- Innogenetics
- Merck & Co.
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- Umeå University
- United States Department of Defense
- University of Liverpool
- University of Southern California